Key result
Overexpression of the myocardial creatine transporter in mice led to left ventricular dilatation and reduced ejection fraction.
Why the study?
Does overexpression of the myocardial creatine transporter affect cardiac function and energy metabolism in mice?
Does overexpression of the myocardial creatine transporter affect cardiac function and energy metabolism in mice?
Supranormal levels of myocardial creatine and phosphocreatine via creatine transporter overexpression lead to energetic impairment, LV hypertrophy, and dysfunction, cautioning against the uncritical use of creatine as a therapeutic agent in heart disease.
Answers are grounded in this paper and cite their sources.
Supranormal myocardial creatine may impair LV function in mice; leaves open effects of creatine supplementation in human heart disease.
BACKGROUND: Heart failure is associated with deranged cardiac energy metabolism, including reductions of creatine and phosphocreatine. Interventions that increase myocardial high-energy phosphate stores have been proposed as a strategy for treatment of heart failure. Previously, it has not been possible to increase myocardial creatine and phosphocreatine concentrations to supranormal levels because they are subject to tight regulation by the sarcolemmal creatine transporter (CrT). METHODS AND RESULTS: We therefore created 2 transgenic mouse lines overexpressing the myocardial creatine transporter (CrT-OE). Compared with wild-type (WT) littermate controls, total creatine (by high-performance liquid chromatography) was increased in CrT-OE hearts (66+/-6 nmol/mg protein in WT versus 133+/-52 nmol/mg protein in CrT-OE). Phosphocreatine levels (by 31P magnetic resonance spectroscopy) were also increased but to a lesser extent. Surprisingly, CrT-OE mice developed left ventricular (LV) dilatation (LV end-diastolic volume: 21.5+/-4.3 microL in WT versus 33.1+/-9.6 microL in CrT-OE; P=0.002), substantial LV dysfunction (ejection fraction: 64+/-9% in WT versus 49+/-13% in CrT-OE; range, 22% to 70%; P=0.003), and LV hypertrophy (by 3-dimensional echocardiography and magnetic resonance imaging). Myocardial creatine content correlated closely with LV end-diastolic volume (r=0.51, P=0.02), ejection fraction (r=-0.74, P=0.0002), LV weight (r=0.59, P=0.006), LV end-diastolic pressure (r=0.52, P=0.02), and dP/dt(max) (r=-0.69, P=0.0008). Despite increased creatine and phosphocreatine levels, CrT-OE hearts showed energetic impairment, with increased free ADP concentrations and reduced free-energy change levels. CONCLUSIONS: Overexpression of the CrT leads to supranormal levels of myocardial creatine and phosphocreatine, but the heart is incapable of keeping the augmented creatine pool adequately phosphorylated, resulting in increased free ADP levels, LV hypertrophy, and dysfunction. Our data demonstrate that a disturbance of the CrT-mediated tight regulation of cardiac energy metabolism has deleterious functional consequences. These findings caution against the uncritical use of creatine as a therapeutic agent in heart disease.
No takes yet. Share an insight, caveat, or question.
Wallis et al. (2005) studied Heart failure. Overexpression of the myocardial creatine transporter (CrT-OE) vs. Wild-type (WT) littermate controls was evaluated on Left ventricular ejection fraction (p=0.003). Overexpression of the myocardial creatine transporter in mice led to left ventricular dilatation and reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: